Sugi Predict

Sugi Predict / Compounds / SCHEMBL19971534

SCHEMBL19971534

SCHEMBL19971534

CCOC(=O)CC(=O)c1cc(Cl)c(Cl)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MGAM O43451 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SI P14410 1/20 0.41
▸ MGAM2 Q2M2H8 1/20 0.41
▸ CASP1 P29466 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ NLRP3 Q96P20 1/20 0.38
▸ MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30297970 1.00 MIF (0.43) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL1389163 0.85 KEAP1 (0.51) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL29980061 0.85 KEAP1 (0.51) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL13004014 0.81 MIF (0.41) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL9775952 0.79 MIF (0.40) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL29980368 0.79 PKM (0.43) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL2082473 0.79 PKM (0.43) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL5872059 0.79 EGFR (0.44) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL7008919 0.78 MEN1 (0.44) MIFKDM4EALDH1A1MEN1KMT2A
SCHEMBL9775891 0.78 MIF (0.41) MIFKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1003236-B Preparation method of 6, 7-disubstituted-1-cyclopropyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid 拜尔公司 1989-02-08 — — CN claimed
CN-118201914-A 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors 雷多纳治疗公司 2024-06-14 — — CN disclosed
CN-116157392-A Compounds targeting RNA binding proteins or RNA modification proteins 雷多纳治疗公司 2023-05-23 — — CN disclosed
CN-115554294-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2023-01-03 — — CN disclosed
CN-115477649-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-16 — — CN disclosed
CN-115429798-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-06 — — CN disclosed
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 — — US disclosed
CN-109689656-B 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-10-04 — — CN disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 — — US disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
EP-3512849-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2019-07-24 — — EP disclosed
WO-2018050510-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-22 — — WO disclosed
EP-3296298-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2018-03-21 — — EP disclosed
CN-86100126-A 6, the two replacement-1-cyclopropyl of 7--1,4 dihydro-4-oxo-1, the preparation method and the application thereof of 8-naphthyridines-3-carboxylic acid — 1986-07-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 MIF 4279/4885KDM4E 3765/4885ALDH1A1 417/4885
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 MIF 4279/4885KDM4E 3765/4885ALDH1A1 417/4885
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 MIF 4279/4885KDM4E 3765/4885ALDH1A1 417/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 MIF 4279/4885KDM4E 3765/4885ALDH1A1 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.